TVTX Q4 2025 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$130M+73.4% YoY

Gross Profit

$109M84.0% margin

Operating Income

-$32M-25.0% margin

Net Income

-$22M-17.0% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

-21.3%

Cash Flow

Operating Cash Flow

$61M

Free Cash Flow

$61M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$605M

Total Liabilities

$490M

Stockholders' Equity

$115M

Cash & Equivalents

$93M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$130M	$75M	+73.4%
Gross Profit	$109M	$72M	+50.9%
Operating Income	-$32M	-$61M	+46.6%
Net Income	-$22M	-$60M	+63.5%

Revenue Segments

Product

$221M99%

License

$3M1%